Stockscreener 앱 받기
66.86
1.05%
-0.71
시간 외 거래:
66.86
전일 마감가:
$67.57
열려 있는:
$67.23
하루 거래량:
1.78M
Relative Volume:
2.06
시가총액:
$10.62B
수익:
$1.17B
순이익/손실:
$150.71M
주가수익비율:
43.99
EPS:
1.52
순현금흐름:
$245.03M
1주 성능:
-10.48%
1개월 성능:
-6.15%
6개월 성능:
-20.22%
1년 성능:
+9.52%
1일 변동 폭
$65.99
$67.49
1주일 범위
$65.99
$76.43
52주 변동 폭
$61.11
$85.57
바이오-테크네 Stock (TECH) Company Profile
명칭
Bio Techne Corp
전화
(612) 379-8854
주소
614 MCKINLEY PL N E, MINNEAPOLIS, MN
TECH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| TECH | 66.86 | 10.62B | 1.17B | 150.71M | 245.03M | 1.52 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
바이오-테크네 Stock (TECH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-02-08 | 개시 | Scotiabank | Sector Outperform |
| 2024-02-02 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-07 | 개시 | UBS | Buy |
| 2023-08-28 | 개시 | William Blair | Outperform |
| 2023-01-10 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-12-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-12-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-04-25 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | 업그레이드 | Stifel | Hold → Buy |
| 2021-01-25 | 재확인 | The Benchmark Company | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | 개시 | Atlantic Equities | Overweight |
| 2020-07-15 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-05-14 | 개시 | The Benchmark Company | Buy |
| 2020-01-08 | 재개 | Stephens | Overweight |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-07-02 | 업그레이드 | Janney | Neutral → Buy |
| 2019-01-14 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2018-10-17 | 개시 | Goldman | Neutral |
| 2018-06-15 | 개시 | Argus | Buy |
| 2017-07-13 | 개시 | Wells Fargo | Market Perform |
| 2017-02-09 | 개시 | Citigroup | Buy |
| 2017-01-18 | 개시 | Deutsche Bank | Buy |
| 2016-11-10 | 재개 | Leerink Partners | Outperform |
| 2015-01-21 | 재확인 | Robert W. Baird | Outperform |
| 2013-09-20 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
모두보기
바이오-테크네 주식(TECH)의 최신 뉴스
BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH - Yahoo Finance
Broadcrest Asset Management LLC Has $15.99 Million Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Royce & Associates LP Acquires 17,296 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
BIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO - Quantisnow
Geneva Capital Management LLC Has $88.27 Million Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Sumitomo Mitsui Trust Group Inc. Cuts Stock Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne To Present At UBS Global Healthcare Conference; Webcast At 12:30 PM ET - Nasdaq
Bio-Techne (NASDAQ:TECH) Raised to Buy at StockNews.com - MarketBeat
UPDATED: BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS - Quantisnow
BIO-TECHNE TO PRESENT AT INVESTOR CONFERENCES - Marketscreener.com
BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS - Quantisnow
Bio-Techne Co. (NASDAQ:TECH) is Montanaro Asset Management Ltd's 3rd Largest Position - MarketBeat
Ownership Capital B.V. Sells 208,493 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
When the Price of (TECH) Talks, People Listen - Stock Traders Daily
Bio-Techne Corporation: An Insight Into Its Market Position & Product Expansion in Diagnostics and Spatial Biology!Major Drivers - Smartkarma
Bio-Techne Gears Up for Q1 Earnings Release: What's in the Cards? - MSN
Asset Management One Co. Ltd. Has $9.69 Million Stock Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
ScaleReady Announces multiple G-Rex® Grants have been awarded to leading investigators at the Baylor College of Medicine's Center for Cell and Gene Therapy - Quantisnow
Bio-Techne Co. (NASDAQ:TECH) Shares Sold by Van ECK Associates Corp - MarketBeat
There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings - Yahoo Finance
Ex-Dividend Reminder: Bio-Techne, Pfizer and Tompkins Financial - Nasdaq
BIO-TECHNE TO PRESENT AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 39TH ANNUAL MEETING - WV News
Beyond the Balance Sheet: What SWOT Reveals About Bio-Techne Corp (TECH) - Yahoo Finance
Bio-Techne (FRA:TE1) Change In Receivables : €-33 Mil (TTM As of Sep. 2024) - GuruFocus.com
Bio-Techne Corporation (TECH) Announces Executive Compensation U - GuruFocus.com
Bio-Techne awards CFO restricted stock units for retention - Investing.com
TECH (Bio-Techne) 5-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
LUNAPHORE COMET™ PLATFORM PAVES THE WAY FOR SPATIAL BIOLOGY ADOPTION IN CLINICAL RESEARCH - Quantisnow
Bio-Techne Co. (NASDAQ:TECH) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Bio-Techne Tops Q1 Earnings & Revenue Estimates, Stock Up in Premarket - MSN
Bio-Techne Corp (TECH)'s Winning Formula: Financial Metrics and Competitive Strengths - GuruFocus.com
New York State Common Retirement Fund Reduces Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne (NASDAQ:TECH) Upgraded to Buy at StockNews.com - MarketBeat
9 Best Biotech Stocks Of November 2024 - Forbes
Bio-Techne Corporation (NASDAQ:TECH) Q1 2025 Earnings Call Transcript - Insider Monkey
TECH (Bio-Techne) Total Inventories : $185 Mil (As of Sep. 2024) - GuruFocus.com
Bio-Techne Tops Profit Forecasts Thanks To Booming Diagnostics - Finimize
Bio-Techne shares target raised, outperform on strong Q1 results By Investing.com - Investing.com Australia
Earnings call: Bio-Techne reports steady growth in Q1 FY2025 - Investing.com
Earnings call: Bio-Techne reports steady growth in Q1 FY2025 By Investing.com - Investing.com UK
Bio-Techne shares target raised, outperform on strong Q1 results - Investing.com India
Robert W. Baird Forecasts Strong Price Appreciation for Bio-Techne (NASDAQ:TECH) Stock - MarketBeat
Bio-Techne Corp (TECH) Q1 2025 Earnings Call Highlights: Navigat - GuruFocus.com
Bio-Techne Corp (TECH) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges in a ... - Yahoo Finance
Bio-Techne holds at $80 target with Overweight rating - Investing.com India
Bio-Techne holds at $80 target with Overweight rating By Investing.com - Investing.com South Africa
Objective long/short (TECH) Report - Stock Traders Daily
Bio-Techne Q1 25 Earnings Conference Call At 9:00 AM ET - Nasdaq
Bio-Techne beats quarterly profit estimates, driven by diagnostic unit growth; shares rise - Reuters.com
Bio-Techne Corp (TECH) Q1 FY2025 Earnings: Revenue Surpasses Est - GuruFocus.com
Bio-Techne earnings beat by $0.04, revenue topped estimates - Investing.com
바이오-테크네 (TECH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):